adMare
News
November 15 2024
Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025ucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing
November 12 2024
Zucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing
October 25 2024
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
October 24 2024
Cancer Research UK and KisoJi Biotechnology Collaborate to Advance the First Naked Antibody Against TROP2 Into the Clinic
October 22 2024
adMare BioInnovations Celebrates Successes of adMare Tx Accelerator Companies, Concludes Ontario Partnership with MaRS
October 21 2024
Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101
October 15 2024
Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients
October 02 2024
Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment
September 18 2024
NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases
September 16 2024
Find Therapeutics Announces the Closing of a Convertible Note Financing with Investissement Québec
Newsletter
Stay up to date on the
latest adMare news
Vancouver Innovation Centre
2405 Wesbrook Mall
Vancouver, British Columbia, Canada
V6T 1Z3
T. 604.827.1147
Toronto Office
MaRS Centre, West Tower
661 University Ave., Suite 405
Toronto, Ontario, Canada
M5G 1M1
T. 416.673.8100
Montreal Innovation Centre
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
